Healthcare giant Merck & Co., Inc. reported Tuesday a profit for the second quarter that plunged 66 percent from last year, hurt by significantly higher charges and R&D costs as well as a double-digit revenue decline. However, stripping down charges, adjusted earnings per share topped analysts’ expectations, while quarterly revenues missed their estimates by a whisker.